Why this peptide is on people's radar
LL-37 sits at the heart of a real and important corner of immunology. It's part of the body's innate antimicrobial defense, peptides released by white blood cells and barrier-tissue epithelial cells (skin, gut, lungs) that kill pathogens directly, before adaptive immunity has time to recognize them. The growing antibiotic-resistance crisis has driven research interest in antimicrobial peptides as alternatives to traditional antibiotics, and LL-37 is among the most-studied human antimicrobial peptides.
The research-peptide community pulled LL-37 out of the academic immunology literature into broader awareness through interest in chronic infection, biofilm-resistant bacteria, post-surgical wound healing, and immune-supporting protocols. Some clinicians have used it off-label for chronic Lyme disease, persistent infections, and post-acute infection contexts. The published-trial evidence for those uses is much thinner than the popular framing suggests.
The complication that makes LL-37 different from most peptides on this site: in autoimmune skin diseases like psoriasis, rosacea, and lupus, LL-37 is implicated as a driver of the inflammatory cascade. Elevated LL-37 levels in psoriatic skin contribute to the disease pathology. That's not a hypothetical concern, it's well-documented immunology. People with autoimmune skin conditions have a genuinely different risk picture for LL-37 than people without those conditions.
What people are usually trying to do with it
People exploring LL-37 are usually focused on:
- Persistent or recurrent infections that haven't responded to standard antibiotics
- Biofilm-resistant bacterial infections (chronic wounds, urinary tract, ENT)
- Wound healing support, especially in slow-healing wounds
- Post-acute infection support (post-Lyme, post-mononucleosis, etc.)
- Adjunct support during chronic infection treatment
What the science actually shows
Plain-English summary:
Broad-spectrum antimicrobial activity
Well-documented in vitro across bacteria (Gram-positive and Gram-negative), fungi, viruses, and some parasites. Mechanism involves membrane disruption plus immunomodulation.
Wound healing and immune signaling
Animal and cell-culture studies show LL-37 supports wound healing through angiogenesis, keratinocyte migration, and modulation of the inflammatory response.
Implication in autoimmune skin disease
In psoriasis specifically, LL-37 binds self-DNA and activates plasmacytoid dendritic cells, contributing to the inflammatory cascade that drives the disease. Elevated LL-37 is a feature of psoriatic skin. Similar mechanisms have been implicated in rosacea and aspects of lupus.
What hasn't been demonstrated
FDA-approved indication. Rigorous human clinical trials of synthetic LL-37 for chronic infection. Long-term safety in healthy adults using LL-37 for general immune support. Whether the antimicrobial benefits outweigh the autoimmune-disease activation risk in patients with relevant conditions.
The honest read
What's solid:
LL-37 is a real human innate-immunity peptide with well-characterized antimicrobial mechanisms. The biology is interesting, the antibiotic-resistance angle is real, and animal-and-cellular evidence for the antimicrobial and wound-healing effects is consistent.
What's still unproven:
Whether synthetic exogenous LL-37 produces the antimicrobial benefits people want in real-world chronic-infection contexts. The clinical-trial evidence is thin. Effects on chronic Lyme, post-acute infection, and similar use cases are mostly anecdotal.
What's a real concern:
Autoimmune skin disease activation. People with psoriasis, rosacea, lupus, or family history of these conditions should treat the LL-37 / autoimmune-driver biology as a meaningful concern, not a distant theoretical issue. The mechanism by which LL-37 drives psoriasis pathology is well-documented, and exogenous LL-37 in someone predisposed to those conditions could plausibly worsen rather than help.
What's hyped beyond the evidence:
"Natural antibiotic" framings that ignore the autoimmune complications. "Immune system booster" claims without specifying which conditions and patient populations the evidence supports. Marketing that treats LL-37 as broadly applicable in immune support overlooks the genuinely two-edged biology.
Things to know if you're looking into it
- Two-edged immunology: antimicrobial in some contexts, autoimmune-driving in others. The same peptide.
- Autoimmune-disease screening matters: personal or family history of psoriasis, rosacea, lupus, or other autoimmune conditions is a meaningful red flag for considering LL-37.
- How it's used in research: typically subcutaneous or topical. Topical routes are more common for wound applications.
- Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
- Healthcare provider involvement: recommended, especially given the autoimmune context. Anyone with chronic infection serious enough to consider experimental antimicrobial peptides should be working with infectious-disease specialists.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Is LL-37 a natural antibiotic?
It's part of your innate immune system's antimicrobial response. Whether you should think of synthetic LL-37 as a "natural antibiotic" alternative is a different question, the clinical-trial evidence for that use case is much thinner than the framing suggests.
Will it help with chronic Lyme?
Some clinicians use it off-label in that context. Rigorous evidence for benefit specifically in chronic Lyme is essentially absent. Anyone with persistent Lyme-related symptoms should be working with appropriate specialists.
Is it safe?
Generally well-tolerated in research-community use, but with the meaningful caveat that LL-37 is implicated in autoimmune skin disease pathology. People with psoriasis, rosacea, lupus, or family history of these should treat that as a real concern.
Is it FDA-approved?
No. Not approved for any indication.
How is it different from regular antibiotics?
Different mechanism. Antibiotics typically target specific bacterial proteins or pathways. LL-37 acts on bacterial cell membranes more broadly and combines that with immune-signaling effects. Some hope it might be less prone to bacterial resistance development; whether that holds in practice isn't established.
Can I use it for my acne?
Acne involves complex immune-skin biology where LL-37's role isn't entirely clean. Acne also has well-evidenced FDA-approved treatments. LL-37 isn't a sensible first-line approach.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. Status updates land here when they happen.
Want to go deeper?
Mechanism, the autoimmune complication, and references.
Background
LL-37 is the 37-amino-acid C-terminal active form of human cathelicidin antimicrobial peptide (CAMP gene product, processed from hCAP-18). Released by neutrophils, monocytes, mast cells, and barrier-tissue epithelial cells. Part of the innate antimicrobial defense system shared with related cathelicidins across mammals.
Mechanism of action
Direct antimicrobial activity
LL-37 has an amphipathic structure (hydrophilic on one face, hydrophobic on the other) that lets it integrate into bacterial cell membranes and disrupt them. Active against Gram-positive and Gram-negative bacteria, fungi, enveloped viruses, and some parasites.
Immunomodulation
Beyond direct killing, LL-37 modulates the immune response, promoting wound healing, supporting angiogenesis, recruiting and activating immune cells, and influencing cytokine production.
Autoimmune-disease driver (in psoriasis specifically)
In psoriasis, LL-37 binds self-DNA released from damaged keratinocytes, forming complexes that activate plasmacytoid dendritic cells via TLR9. The resulting interferon production initiates the T-cell-mediated inflammatory cascade central to psoriasis. Elevated LL-37 is a feature of psoriatic skin and contributes to disease pathology.
References
- Vandamme D, Landuyt B, Luyten W, Schoofs L. (2012). "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cell Immunol, 280(1), 22–35. PubMed
- Heilborn JD, Nilsson MF, Kratz G, et al. (2003). "The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds." J Invest Dermatol, 120(3), 379–389. PubMed
- Lande R, Gregorio J, Facchinetti V, et al. (2007). "Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide." Nature, 449(7162), 564–569. PubMed
- Reinholz M, Ruzicka T, Schauber J. (2012). "Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease." Ann Dermatol, 24(2), 126–135. PubMed